GO:0019828 aspartic-type endopeptidase inhibitor activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0019828 describes a molecular function: the binding of a protein or peptide to an aspartic-type endopeptidase (aspartic protease) in a way that stops, prevents or reduces its proteolytic activity.
• Aspartic protease inhibitors are best known as drug-like molecules and natural regulators that block viral and fungal aspartic proteases, including HIV-1 protease and Candida albicans secreted aspartic proteases.
• Microbial pathogens such as Candida albicans, Trichosporon asahii and Phialophora verrucosa secrete aspartic peptidases whose activity can be blocked by aspartic protease inhibitors, linking this GO term to antifungal and anti-virulence strategies.
• The function is defined by binding and inhibition, not by catalysis, so the gene products annotated to GO:0019828 include protease inhibitors, inhibitor domains and inhibitor-like proteins rather than the proteases themselves.
• Studying GO:0019828 experimentally requires combining enzyme activity assays, inhibitor binding assays and genetic perturbation of inhibitor-encoding genes.
• CRISPR knockout, point-mutation, knock-in and overexpression models allow causal testing of whether a candidate inhibitor gene truly regulates aspartic protease activity in a given biological context.
Description
GO:0019828, aspartic-type endopeptidase inhibitor activity, is a molecular function term in the Gene Ontology that describes the ability of a gene product to bind to and stop, prevent or reduce the activity of an aspartic-type endopeptidase. Aspartic-type endopeptidases, also called aspartic proteases, are enzymes that use two catalytic aspartate residues to hydrolyze peptide bonds, and they are widely distributed in viruses, fungi, parasites and humans. The inhibitors annotated to GO:0019828 therefore act as brakes on this class of proteolytic enzymes, and their study is central to understanding proteolytic balance in infection, immunity and disease. The importance of this term is illustrated by the HIV-1 protease, a retroviral aspartic protease that became the target of highly successful inhibitor-based therapy. The same conceptual framework applies to fungal pathogens, where secreted aspartic peptidases contribute to virulence and where aspartic protease inhibitors can interfere with fungal growth and host interaction. In Candida albicans, aspartic protease inhibitors have been studied as potential anti-Candida drugs with impacts on fungal biology, virulence and pathogenesis. In Phialophora verrucosa, an aspartic peptidase is blocked by HIV peptidase inhibitors, and this blockage interferes with fungal growth and macrophage interaction. These examples show that GO:0019828 is not an abstract annotation but a functionally actionable activity with direct relevance to antimicrobial and antiviral research. For researchers, GO:0019828 provides a precise way to annotate and search for inhibitor functions that act specifically on aspartic proteases, distinguishing them from inhibitors of serine, cysteine or metalloproteases. Because proteases and their inhibitors control many physiological and pathological events in microorganisms, the study of aspartic-type endopeptidase inhibitor activity connects molecular enzymology to infection biology, drug discovery and cell-model engineering.
aspartic-type endopeptidase inhibitor activity At A Glance
| GO ID | GO:0019828 |
|---|---|
| GO term | aspartic-type endopeptidase inhibitor activity |
| Ontology | molecular_function |
| Synonym | aspartic protease inhibitor activity |
| Definition | Binds to and stops, prevents or reduces the activity of aspartic-type endopeptidases. |
| Major function | Negative regulation of aspartic-type endopeptidase (aspartic protease) activity by direct binding. |
| Target enzyme class | Aspartic-type endopeptidases, including retroviral and fungal aspartic proteases. |
| Representative contexts | Antiviral inhibition of HIV-1 protease and antifungal inhibition of Candida and other fungal aspartic peptidases. |
| Related activity | Protease inhibitor activity in general, as opposed to protease catalytic activity. |
What Is GO:0019828?
In plain terms, GO:0019828 means a protein or peptide binds to an aspartic-type endopeptidase and reduces or blocks its ability to cut other proteins. The official Gene Ontology definition states that this activity binds to and stops, prevents or reduces the activity of aspartic-type endopeptidases. It is a molecular_function term, and its synonym is aspartic protease inhibitor activity. The term describes the inhibitor side of the interaction, not the protease side, so a gene product annotated to GO:0019828 is expected to act as a negative regulator of aspartic protease catalysis.
Why Is aspartic-type endopeptidase inhibitor activity Important in Cell Biology?
GO:0019828 matters because aspartic proteases participate in essential biological processes ranging from viral maturation to fungal virulence, and their inhibitors are both natural regulators and therapeutic leads. The HIV-1 protease is the classic example of a retroviral aspartic protease that became the target of a most promising HIV therapy through inhibitor design. In fungi, secreted aspartic peptidases contribute to host interaction and pathogenesis, and aspartic protease inhibitors can reduce fungal growth and virulence-associated phenotypes. Annotating and studying this activity therefore supports drug discovery, virulence research and the engineering of cell models in which aspartic protease activity is experimentally controlled.
• Provides a Gene Ontology annotation for proteins that negatively regulate aspartic proteases, enabling precise functional genomics and enrichment analysis.
• Underpins antiviral strategies targeting retroviral aspartic proteases such as HIV-1 protease.
• Supports antifungal research, since Candida albicans aspartic protease inhibitors affect fungal biology, virulence and pathogenesis.
• Connects to pathogen-secreted peptidases, including the 30-kDa aspartic peptidase of Trichosporon asahii and the aspartic peptidase of Phialophora verrucosa.
• Helps distinguish aspartic protease inhibition from inhibition of serine proteases such as the 50 kDa serine proteinase of Candida guilliermondii.
• Relevant to microbial physiology and pathological events driven by protease expression.
• Guides design of enzyme activity assays and inhibitor binding assays for drug screening.
• Enables CRISPR-based causal testing of candidate inhibitor genes in infection and cell-biology models.
• Supports comparative studies of protease inhibitors across viruses, fungi and parasites.
• Provides a framework for engineering cell lines with controlled aspartic protease inhibition for mechanistic studies.
Molecular Mechanism of aspartic-type endopeptidase inhibitor activity
Recognition and binding of the aspartic protease target
In simple terms: The inhibitor first has to find and stick to the aspartic protease.
Aspartic-type endopeptidase inhibitors annotated to GO:0019828 function by binding to their target aspartic protease. This binding is the defining event of the term, because the Gene Ontology definition specifies that the inhibitor binds to and stops, prevents or reduces the activity of aspartic-type endopeptidases. In experimental systems, inhibitor binding to fungal aspartic peptidases has been demonstrated through enzymatic activity blockage, for example when HIV peptidase inhibitors block the aspartic peptidase of Phialophora verrucosa. Similarly, aspartic protease inhibitors have been studied for their impacts on Candida albicans biology and virulence, consistent with direct target engagement.
Blocking the catalytic action of the aspartic protease
In simple terms: Once bound, the inhibitor prevents the protease from cutting its protein substrates.
Aspartic proteases use a catalytic mechanism dependent on aspartate residues, and inhibitors that bind these enzymes reduce or abolish substrate cleavage. The retroviral protease field established that inhibition of an aspartic protease can block a critical maturation step, which is why HIV-1 protease became the target of a most promising HIV therapy. In fungi, blockage of aspartic peptidase enzymatic activity by HIV peptidase inhibitors interferes with fungal growth and macrophage interaction, showing that the inhibitory function has measurable biological consequences. These observations support the general principle that GO:0019828 activity reduces aspartic protease-dependent proteolysis.
Downstream consequences for pathogen biology
In simple terms: When the protease is inhibited, processes that depend on it, such as growth or host interaction, can be impaired.
Aspartic peptidases secreted by microorganisms are relevant to crucial physiological and pathological events. In Candida albicans, aspartic protease inhibitors have impacts on fungal biology, virulence and pathogenesis, indicating that inhibition of this enzyme class can alter disease-related traits. In Phialophora verrucosa, blockage of aspartic peptidase activity interferes with fungal growth and macrophage interaction. Trichosporon asahii secretes a 30-kDa aspartic peptidase, further illustrating that aspartic peptidases are common microbial effectors whose inhibition may affect microbial behavior. These findings link the molecular function of GO:0019828 to organism-level outcomes.
Specificity relative to other protease inhibitor classes
In simple terms: This activity is specific for aspartic proteases, not for every kind of protease.
GO:0019828 is restricted to inhibitors of aspartic-type endopeptidases, which distinguishes it from inhibitors of other protease classes. For example, Candida guilliermondii can secrete a 50 kDa serine proteinase that cleaves a broad spectrum of proteinaceous substrates, and such serine protease activity would not be the target of an aspartic-type endopeptidase inhibitor. Protease expression by microorganisms is diverse and relevant to physiological and pathological events, so correct annotation of inhibitor specificity is important for interpreting functional studies. This specificity is also why aspartic protease inhibitors are discussed as a distinct therapeutic class.
Regulation and experimental control of inhibitor activity
In simple terms: The amount and availability of the inhibitor determine how much protease activity remains.
The functional output of GO:0019828 depends on the presence, abundance and localization of the inhibitor relative to its aspartic protease target. Experimental control of inhibitor activity can be achieved by adding exogenous inhibitors, as in studies where HIV peptidase inhibitors block a fungal aspartic peptidase, or by genetically perturbing inhibitor-encoding genes. Because aspartic proteases participate in viral maturation and fungal virulence, manipulating inhibitor levels is a practical way to test causality in infection models. Such experiments connect the molecular function to measurable phenotypes such as growth, host interaction and pathogenesis.
Key Genes Involved in GO:0019828 aspartic-type endopeptidase inhibitor activity
The following genes and gene products are representative of aspartic protease biology and aspartic-type endopeptidase inhibitor activity, based on the verified literature on viral, fungal and parasitic proteases and their inhibitors.
| Gene | Major Role | Research Relevance |
|---|---|---|
| HIV-1 gag-pol (pol-encoded protease) | Encodes the retroviral aspartic protease essential for viral maturation | Classic target of aspartic protease inhibitors and the basis of HIV therapy |
| Candida albicans SAP family (secreted aspartic proteases) | Secreted aspartic proteases linked to fungal biology and virulence | Aspartic protease inhibitors studied as potential anti-Candida drugs |
| Trichosporon asahii aspartic peptidase (30-kDa) | Secreted aspartic peptidase from a fungal pathogen | Model for studying secreted aspartic peptidase inhibition |
| Phialophora verrucosa aspartic peptidase | Fungal aspartic peptidase involved in growth and macrophage interaction | Blocked by HIV peptidase inhibitors; model for antifungal inhibitor testing |
| Candida guilliermondii serine proteinase (50 kDa) | Secreted serine proteinase with broad substrate range | Contrast for specificity of aspartic versus serine protease inhibition |
| Microbial protease genes (general) | Protease expression relevant to physiological and pathological events | Framework for understanding protease inhibitor function in microorganisms |
| Toxocara canis proteinases | Proteinases present in perivitelline fluid from hatching eggs | Parasite protease context for comparative inhibitor studies |
| Retroviral protease (general) | Aspartic protease class enzyme from retroviruses | Structural and functional basis for inhibitor design |
| Fungal secreted aspartic peptidases (general) | Extracellular proteases that interact with host tissues | Targets for inhibitor-based anti-virulence strategies |
| Aspartic protease inhibitor domains (general) | Protein modules that bind and inhibit aspartic proteases | Annotated to GO:0019828 as inhibitor functions |
| HIV-1 protease dimer | Homodimeric aspartic protease with catalytic aspartates | Model for understanding inhibitor binding and resistance |
| Candida albicans virulence-associated proteases | Proteases contributing to pathogenesis | Used to test whether inhibitors reduce virulence traits |
| Phialophora verrucosa growth-related peptidase | Peptidase affecting fungal growth | Readout for inhibitor interference with growth |
| Macrophage interaction-related fungal factors | Host interaction processes influenced by fungal peptidases | Used to assess inhibitor effects on host-pathogen interaction |
| Trichosporon asahii secreted peptidase | Secreted enzyme from an opportunistic fungus | Biochemical target for inhibitor characterization |
| Parasite hatching-associated proteinases | Proteinases active during egg hatching | Comparative model for protease inhibitor studies |
How Is aspartic-type endopeptidase inhibitor activity Regulated?
The activity described by GO:0019828 is regulated at the level of inhibitor availability and target accessibility rather than by a single universal pathway. In experimental settings, aspartic protease inhibitor activity can be modulated by adding exogenous inhibitors, as shown when HIV peptidase inhibitors block the aspartic peptidase of Phialophora verrucosa and interfere with fungal growth and macrophage interaction. In Candida albicans, aspartic protease inhibitors affect fungal biology, virulence and pathogenesis, indicating that the balance between protease and inhibitor influences disease-related outcomes. Because protease expression by microorganisms is relevant to crucial physiological and pathological events, the functional impact of aspartic-type endopeptidase inhibitor activity depends on the specific pathogen, host environment and target protease. Genetic control of inhibitor-encoding genes provides an additional layer of regulation that can be tested experimentally.
aspartic-type endopeptidase inhibitor activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| HIV-1 pol-encoded protease | HIV/AIDS; retroviral maturation | In vitro protease inhibition assays and viral replication models |
| Candida albicans SAP family | Candidiasis; fungal virulence and pathogenesis | Fungal growth and virulence assays with aspartic protease inhibitors |
| Phialophora verrucosa aspartic peptidase | Fungal growth and macrophage interaction | Inhibitor treatment combined with growth and macrophage interaction assays |
| Trichosporon asahii aspartic peptidase | Fungal secreted peptidase biology | Biochemical characterization of the 30-kDa peptidase and inhibitor testing |
| Candida guilliermondii serine proteinase | Microbial protease biology (specificity control) | Substrate cleavage assays to contrast serine versus aspartic protease inhibition |
HIV/AIDS and retroviral protease inhibition
The HIV-1 protease is a retroviral aspartic protease that became the target of a most promising HIV therapy, making aspartic protease inhibition one of the most successful examples of rational drug design against a viral enzyme. GO:0019828 captures the inhibitor side of this interaction, and the clinical success of HIV protease inhibitors demonstrates that blocking an aspartic protease can have major therapeutic benefit. This history provides a template for understanding how aspartic-type endopeptidase inhibitor activity can be harnessed against other pathogens.
Candida infections and antifungal strategies
Candida albicans secretes aspartic proteases that contribute to fungal biology, virulence and pathogenesis, and aspartic protease inhibitors have been evaluated as potential anti-Candida drugs. Inhibiting these enzymes can affect fungal traits relevant to infection, supporting the idea that GO:0019828-related functions are important in antifungal research. Because Candida infections are a clinical concern, understanding how aspartic protease inhibitors act on fungal cells may inform new anti-virulence approaches.
Fungal pathogen growth and host interaction
In Phialophora verrucosa, an aspartic peptidase is blocked by HIV peptidase inhibitors, and this blockage interferes with fungal growth and macrophage interaction. This example links aspartic-type endopeptidase inhibitor activity directly to measurable host-pathogen outcomes, including growth restriction and altered macrophage interaction. Trichosporon asahii also secretes a 30-kDa aspartic peptidase, indicating that secreted aspartic peptidases are relevant across fungal pathogens and may be targeted by inhibitors. Together, these studies show that GO:0019828 is relevant to fungal disease biology beyond a single species.
Parasitic and microbial protease contexts
Protease expression by microorganisms is relevant to crucial physiological and pathological events, and parasite proteinases such as those in Toxocara canis perivitelline fluid illustrate the broader diversity of protease biology. Although the verified literature does not establish a specific aspartic-type endopeptidase inhibitor therapy for these parasites, the general framework of protease inhibition is relevant for comparative studies. Candida guilliermondii serine proteinase studies further highlight the importance of distinguishing protease classes when considering inhibitor specificity.
From aspartic-type endopeptidase inhibitor activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of a candidate inhibitor gene increase aspartic protease activity? | CRISPR knockout of the inhibitor-encoding gene followed by enzyme activity assay |
| Does a specific point mutation abolish inhibitor binding to the aspartic protease? | CRISPR point-mutation knock-in of the inhibitor gene |
| Can a tagged inhibitor be used to measure localization and target engagement? | Tagged knock-in of the inhibitor gene |
| Does overexpression of the inhibitor reduce fungal growth or virulence? | CRISPR overexpression model in fungal cells |
| Does inhibitor treatment alter macrophage interaction with fungal cells? | Inhibitor treatment in macrophage-fungal co-culture |
| Can inhibitor specificity be distinguished from serine protease inhibition? | Comparative assays using serine and aspartic protease substrates |
How to Study the aspartic-type endopeptidase inhibitor activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Aspartic protease activity assay | Cleavage of peptide or protein substrates by aspartic proteases | Testing whether a candidate inhibitor reduces protease activity |
| Inhibitor binding assay | Direct interaction between inhibitor and aspartic protease | Confirming target engagement for GO:0019828-annotated proteins |
| Fungal growth assay | Growth of fungal cells under inhibitor treatment | Linking aspartic protease inhibition to growth phenotypes |
| Macrophage interaction assay | Host cell interaction with fungal pathogens | Assessing whether inhibition alters host-pathogen interaction |
| Biochemical peptidase characterization | Molecular size and enzymatic properties of secreted peptidases | Identifying and validating aspartic peptidase targets |
| Substrate specificity profiling | Range of proteinaceous substrates cleaved by a protease | Distinguishing aspartic from serine protease activity |
| Comparative inhibitor testing | Inhibition across protease classes | Confirming specificity of aspartic-type endopeptidase inhibitor activity |
| Virulence and pathogenesis assays | Disease-related traits of fungal pathogens | Evaluating therapeutic potential of aspartic protease inhibitors |
Enzymatic activity assays for aspartic protease inhibition
The most direct way to study GO:0019828 is to measure aspartic protease activity in the presence and absence of a candidate inhibitor. In Phialophora verrucosa, blockage of aspartic peptidase enzymatic activity by HIV peptidase inhibitors was demonstrated experimentally, providing a template for inhibitor testing. Similar approaches have been used to evaluate aspartic protease inhibitors against Candida albicans, where impacts on fungal biology and virulence were assessed. These assays connect the molecular function to measurable changes in proteolysis.
Microbial growth and host-interaction assays
Because aspartic peptidases contribute to fungal growth and host interaction, inhibitor studies often include growth measurements and macrophage interaction assays. In Phialophora verrucosa, blockage of aspartic peptidase activity interfered with fungal growth and macrophage interaction, showing that the functional consequences of inhibition can be observed at the cellular level. Candida albicans studies similarly link aspartic protease inhibitors to fungal biology, virulence and pathogenesis. These assays help translate molecular inhibition into organism-level phenotypes.
Biochemical characterization of secreted peptidases
Secreted aspartic peptidases can be characterized biochemically, as shown for the 30-kDa aspartic peptidase secreted by Trichosporon asahii. Such characterization provides the target protein needed for inhibitor binding and activity studies. In Candida guilliermondii, a 50 kDa serine proteinase was characterized and shown to cleave a broad spectrum of proteinaceous substrates, illustrating how protease class and substrate range are determined experimentally. These biochemical methods are foundational for studying aspartic-type endopeptidase inhibitor activity.
Comparative and specificity-focused approaches
Because GO:0019828 is specific for aspartic-type endopeptidases, comparative experiments are needed to distinguish it from inhibition of other protease classes. Protease expression by microorganisms is diverse and relevant to physiological and pathological events, so specificity controls are essential when interpreting inhibitor effects. Studies on retroviral proteases provide a structural and mechanistic framework for understanding why inhibitors selectively target aspartic proteases. Together, these approaches ensure that observed inhibition is correctly attributed to aspartic-type endopeptidase inhibitor activity.
How CRISPR Can Be Used to Study GO:0019828 aspartic-type endopeptidase inhibitor activity
Knockout
CRISPR knockout of a candidate inhibitor gene can test whether loss of the inhibitor increases aspartic protease activity or alters pathogen phenotypes. Because aspartic protease inhibitors affect Candida albicans biology and virulence, knockout models can reveal the contribution of specific inhibitor genes to these traits. In fungal systems where aspartic peptidase activity influences growth and macrophage interaction, knockout of inhibitor genes provides a causal test of the GO:0019828 function.
Point Mutation
CRISPR point-mutation models can be used to alter specific residues in an inhibitor or its target protease to test binding and specificity. Such models are useful when a single amino acid change is predicted to affect inhibitor-protease interaction, as in the study of aspartic peptidase inhibition by HIV peptidase inhibitors. Point mutations also help distinguish direct effects on inhibitor activity from indirect effects on protease expression.
Knock-in
Knock-in of tagged or reporter-linked inhibitor genes allows localization and target engagement studies in relevant cell or fungal models. Tagged knock-in can reveal where the inhibitor meets the aspartic protease and whether binding correlates with reduced activity. In Candida albicans, knock-in approaches can be combined with virulence assays to connect inhibitor localization to pathogenesis.
Overexpression
CRISPR overexpression of an aspartic protease inhibitor can test whether increased inhibitor levels reduce protease activity and downstream phenotypes. Overexpression is particularly informative when endogenous inhibitor levels are low or when the goal is to mimic therapeutic inhibition. In fungal models, overexpression of inhibitors may reduce growth or alter macrophage interaction, providing a direct link between GO:0019828 and organism-level outcomes.
How EDITGENE Supports aspartic-type endopeptidase inhibitor activity Research
Researchers studying aspartic-type endopeptidase inhibitor activity-related genes often need to determine whether a candidate gene is causally involved in regulating aspartic protease function, pathogen growth or host interaction. Establishing causality requires precise genetic models in which inhibitor genes can be knocked out, mutated, tagged or overexpressed, followed by functional assays that measure protease activity and downstream phenotypes. EDITGENE provides these CRISPR-based models and supporting bioinformatics to accelerate hypothesis-driven research on GO:0019828 and related protease inhibitor functions.
Contact EDITGENE today to design your custom CRISPR model for aspartic-type endopeptidase inhibitor activity research.
Frequently Asked Questions About aspartic-type endopeptidase inhibitor activity
What is aspartic-type endopeptidase inhibitor activity?
It is the molecular function defined by GO:0019828, in which a protein or peptide binds to and stops, prevents or reduces the activity of an aspartic-type endopeptidase, also called an aspartic protease.
What is the GO ID for aspartic-type endopeptidase inhibitor activity?
The Gene Ontology ID is GO:0019828, and the term belongs to the molecular_function ontology with the synonym aspartic protease inhibitor activity.
What genes are involved in aspartic-type endopeptidase inhibitor activity?
Genes involved include those encoding aspartic protease inhibitors and inhibitor domains, as well as the aspartic protease targets themselves, such as retroviral proteases and fungal secreted aspartic peptidases like those in Candida albicans and Phialophora verrucosa.
How does aspartic-type endopeptidase inhibitor activity work?
The inhibitor binds to the aspartic protease and blocks its catalytic action, reducing cleavage of protein substrates; this has been demonstrated when HIV peptidase inhibitors block a fungal aspartic peptidase.
Why is aspartic-type endopeptidase inhibitor activity important for HIV research?
The HIV-1 protease is a retroviral aspartic protease that became the target of a most promising HIV therapy, making aspartic protease inhibition a cornerstone of antiviral drug development.
Can aspartic protease inhibitors be used against fungal infections?
Yes, aspartic protease inhibitors have been studied as potential anti-Candida albicans drugs with impacts on fungal biology, virulence and pathogenesis, and they can interfere with fungal growth and macrophage interaction in other fungi.
What is the difference between aspartic and serine protease inhibitors?
Aspartic-type endopeptidase inhibitors specifically target aspartic proteases, whereas serine protease inhibitors target enzymes such as the 50 kDa serine proteinase of Candida guilliermondii; the two classes are distinct.
Which experimental methods are used to study aspartic-type endopeptidase inhibitor activity?
Common methods include aspartic protease activity assays, inhibitor binding assays, fungal growth assays, macrophage interaction assays and biochemical characterization of secreted peptidases.
How can CRISPR help study aspartic-type endopeptidase inhibitor activity?
CRISPR knockout, point mutation, knock-in and overexpression models allow researchers to test whether a candidate inhibitor gene causally regulates aspartic protease activity and related phenotypes.
What diseases are linked to aspartic-type endopeptidase inhibitor activity?
The strongest links are to HIV/AIDS through retroviral protease inhibition and to fungal infections such as candidiasis through inhibition of secreted aspartic proteases.
Conclusion
GO:0019828, aspartic-type endopeptidase inhibitor activity, defines a molecular function that is central to controlling aspartic proteases in viruses, fungi and other organisms. The verified literature shows that this activity is experimentally tractable and therapeutically relevant, from HIV protease inhibition to antifungal strategies against Candida albicans and other fungal pathogens. Understanding which genes encode these inhibitors and how they act requires precise genetic models and functional assays. By combining CRISPR knockout, point-mutation, knock-in, overexpression and library screening with biochemical and cellular readouts, researchers can move from annotation to causal mechanism for GO:0019828. This integrated approach supports drug discovery, virulence research and fundamental studies of protease regulation in health and disease.
References
- 1. Valle RS et al.. 2017. Trichosporon asahii secretes a 30-kDa aspartic peptidase.. Microbiol Res 205:66-72 PMID: 28942846
- 2. Braga-Silva LA et al.. 2011. Aspartic protease inhibitors as potential anti-Candida albicans drugs: impacts on fungal biology, virulence and pathogenesis.. Curr Med Chem 18(16):2401-19 PMID: 21568917
- 3. von der Helm K. 1996. Retroviral proteases: structure, function and inhibition from a non-anticipated viral enzyme to the target of a most promising HIV therapy.. Biol Chem 377(12):765-74 PMID: 8997487
- 4. Dos Santos AL. 2011. Protease expression by microorganisms and its relevance to crucial physiological/pathological events.. World J Biol Chem 2(3):48-58 PMID: 21537490
- 5. Dos Santos AL et al.. 2005. Candida guilliermondii isolated from HIV-infected human secretes a 50 kDa serine proteinase that cleaves a broad spectrum of proteinaceous substrates.. FEMS Immunol Med Microbiol 43(1):13-20 PMID: 15607631
- 6. Granato MQ et al.. 2020. Aspartic peptidase of Phialophora verrucosa as target of HIV peptidase inhibitors: blockage of its enzymatic activity and interference with fungal growth and macrophage interaction.. J Enzyme Inhib Med Chem 35(1):629-638 PMID: 32037904
- 7. González-Páez GE et al.. 2007. Toxocara canis: proteinases in perivitelline fluid from hatching eggs.. Vet Parasitol 147(3-4):332-5 PMID: 17517477
